MCID: HYP073
MIFTS: 50

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 15
Immunoproliferative Disorders 45 74
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
MeSH 45 D007160
SNOMED-CT 69 86295000
ICD10 34 C88 C88.9
UMLS 74 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

Disease Ontology : 12 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response.

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to sarcoidosis 1 and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Methylprednisolone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Related Disease Score Top Affiliating Genes
1 sarcoidosis 1 31.8 ACE BTNL2 IL2 NOD2 TNF TNFRSF1B
2 autoimmune lymphoproliferative syndrome 31.6 ARFGAP1 CASP10 FAS FASLG IL2
3 heavy chain disease 11.3
4 cryoglobulinemia 11.3
5 schnitzler syndrome 11.3
6 chronic nk-cell lymphocytosis 11.3
7 lymphoid interstitial pneumonia 11.3
8 uveoparotid fever 10.4 ACE TNF
9 subacute cutaneous lupus erythematosus 10.4 ACE TNF
10 inflammatory bowel disease 20 10.4 MRAP NOD2
11 oral tuberculosis 10.4 IL2 TNF
12 posterior scleritis 10.4 MRAP TNF
13 ileocolitis 10.4 NOD2 TNF
14 skin sarcoidosis 10.3 ACE TNF TNFRSF1B
15 orofacial granulomatosis 10.3 BTNL2 NOD2 TNF
16 kashin-beck disease 10.3 FAS TNF
17 chronic gonococcal salpingitis 10.3 TNF TNFRSF1B
18 vascular dementia 10.3 ACE SERPINA3 TNF
19 streptococcal toxic-shock syndrome 10.3 IL2 TNF
20 autoimmune lymphoproliferative syndrome, type iii 10.3 CASP10 FASLG
21 acute salpingitis 10.3 MRAP TNF TNFRSF1B
22 chronic venous leg ulcers 10.3 FAS FASLG
23 commensal bacterial infectious disease 10.3 BTNL2 IL2 TNF
24 type ii mixed cryoglobulinemia 10.3 FAS FASLG
25 panuveitis 10.3 MRAP TNF TNFRSF1B
26 palindromic rheumatism 10.3 MRAP TNF TNFRSF1B
27 lymphocytic gastritis 10.3 FAS FASLG
28 pulmonary sarcoidosis 10.3 ACE IL2 TNF
29 crohn's colitis 10.3 IL2 NOD2 TNF
30 iritis 10.3 MRAP TNFRSF1B
31 vulvar vestibulitis syndrome 10.3 IL1RN TNF
32 pouchitis 10.3 IL1RN NOD2
33 leprosy 3 10.2 IL2 NOD2 TNF
34 farmer's lung 10.2 IL2 TNF
35 temporal arteritis 10.2 IL1RN SERPINA3 TNF
36 coccidiosis 10.2 IL2 MRAP TNF
37 chagas disease 10.2 ACE IL2 TNF
38 urinary system disease 10.2 ACE IL2 TNF
39 respiratory failure 10.2 ACE ALPL TNF
40 epstein-barr virus-associated gastric carcinoma 10.2 FAS FASLG TNF
41 primary bacterial infectious disease 10.2 IL2 TNF TNFRSF1B
42 granulomatous dermatitis 10.2 ACE NOD2 TNF TNFRSF1B
43 familial mediterranean fever 10.2 IL1RN NOD2 TNF
44 severe cutaneous adverse reaction 10.2 FAS FASLG TNF
45 melkersson-rosenthal syndrome 10.2 ACE NOD2 TNF TNFRSF1B
46 pneumoconiosis 10.2 FAS FASLG TNF
47 waldenstrom macroglobulinemia 10.2
48 alpha-heavy chain disease 10.2
49 intestinal disease 10.2 IL2 NOD2 TNF
50 juvenile rheumatoid arthritis 10.2 IL1RN TNF TNFRSF1B

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 ACE FAS IL2 NOD2 TNF TNFRSF1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 ACE FAS FASLG IL2 NOD2 TNF

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 ALPI ALPL FAS FASLG IL2 NOD2
2 hematopoietic system MP:0005397 9.65 ACE ALPL CCR6 FAS FASLG IL1RN
3 neoplasm MP:0002006 9.1 ACE FAS FASLG IL2 TNF TNFRSF1B

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1067)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
5
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
6
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
7
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
9
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
15
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
17
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
19
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
20
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
21
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
22
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
23
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
24
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53643-48-4, 59917-39-4 40839
25
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
26
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
28
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
29
Ferrous succinate Approved Phase 4 10030-90-7
30
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 15589840 11953898
31
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
32
Iron Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 27284 23925
33
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
34
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
35
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
36
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
37
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
38
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
39
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 460612 4053
40
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 179324-69-7 387447 93860
41
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
42
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3375-50-6 598
43
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
44
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
45
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
46
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53910-25-1 439693 40926
47
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
48
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
49
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
50
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 70789204 6442177

Interventional clinical trials:

(show top 50) (show all 8414)
# Name Status NCT ID Phase Drugs
1 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
2 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
3 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
4 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
5 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
6 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
8 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
9 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
10 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
11 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
12 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
13 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
14 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
15 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
16 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
17 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
18 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
19 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
20 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
21 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
22 Treatment of Natural Killer/T Cell Lymphoma-I/II Unknown status NCT01501136 Phase 4
23 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
24 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
25 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
26 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
27 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
28 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
29 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
30 A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies Completed NCT00776425 Phase 4 Epoetin beta
31 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
32 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
33 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
34 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
35 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
36 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
37 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
38 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
39 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
40 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
41 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
42 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
43 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
44 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
45 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
46 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
47 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
48 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
49 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
50 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

42
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Breast

Publications for Hypersensitivity Reaction Type Iv Disease

Articles related to Hypersensitivity Reaction Type Iv Disease:

(show all 11)
# Title Authors Year
1
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. ( 23161721 )
2012
2
Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. ( 14652716 )
2004
3
Effect of alpha IFN on unaggressive immunoproliferative disorders. ( 7758989 )
1995
4
Atypical immunoproliferative disorders: when of age? ( 8506619 )
1993
5
Structurally abnormal immunoglobulins in human immunoproliferative disorders. ( 1571535 )
1992
6
Immunoproliferative disorders: detection, prevention, and therapeutics. ( 2508454 )
1989
7
Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. ( 6667410 )
1983
8
Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. ( 4216270 )
1974
9
Surface IgD in immunoproliferative disorders. ( 4218365 )
1974
10
Lymphocyte transformation in immunoproliferative disorders. ( 4114813 )
1972
11
M-components in immunoproliferative disorders. Electrophoretic and immunologic analysis of 200 cases. ( 4964131 )
1967

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 BTNL2 CASP10 CCR6 FASLG IFNA1 IL1RN
2
Show member pathways
13.59 CASP10 CCR6 FAS FASLG IFNA1 IL1RN
3
Show member pathways
13.29 FASLG IFNA1 IL1RN IL2 NOD2 TNF
4
Show member pathways
13.1 ARFGAP1 CASP10 CCR6 FAS FASLG IL2
5
Show member pathways
12.88 CASP10 FAS FASLG IFNA1 TNF TNFRSF1B
6
Show member pathways
12.88 ACE FAS FASLG IFNA1 IL2 NOD2
7
Show member pathways
12.74 FAS FASLG IFNA1 IL2 TNF TNFRSF1B
8
Show member pathways
12.73 CASP10 FAS FASLG TNF TNFRSF1B
9
Show member pathways
12.52 CASP10 FAS FASLG TNF TNFRSF1B
10
Show member pathways
12.35 FAS FASLG IFNA1 IL2 TNF
11
Show member pathways
12.32 CASP10 FAS FASLG TNF TNFRSF1B
12
Show member pathways
12.18 CASP10 FAS FASLG TNF
13 12.14 FAS FASLG TNF TNFRSF1B
14 12.12 CASP10 IFNA1 NOD2 TNF
15
Show member pathways
12.1 ALPG ALPI ALPL ALPP
16
Show member pathways
12.1 CASP10 FAS FASLG TNF TNFRSF1B
17
Show member pathways
12.09 FAS FASLG IFNA1 TNF
18 12.01 FAS FASLG IFNA1 IL1RN IL2 TNF
19
Show member pathways
11.82 ALPG ALPI ALPL
20 11.71 CCR6 IL2 TNF
21 11.7 CASP10 FAS NOD2 TNF TNFRSF1B
22
Show member pathways
11.67 FASLG IL2 TNF
23 11.64 IL1RN IL2 TNF
24
Show member pathways
11.55 FASLG IL2 TNF
25 11.4 IL1RN TNF TNFRSF1B
26 11.33 FAS FASLG TNF
27 11.33 FAS FASLG IL2 TNF
28 11.24 FAS FASLG TNF
29
Show member pathways
10.92 ALPG ALPI ALPL ALPP
30 10.13 ALPG ALPI ALPL ALPP

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 ACE ALPG ALPI ALPL ALPP BTNL2
2 cell surface GO:0009986 9.73 ALPP CCR6 FAS FASLG NOD2 TNF
3 external side of plasma membrane GO:0009897 9.72 ACE BTNL2 CCR6 FASLG TNF
4 membrane raft GO:0045121 9.71 FAS FASLG TNF TNFRSF1B
5 anchored component of membrane GO:0031225 9.46 ALPG ALPI ALPL ALPP
6 extracellular region GO:0005576 9.4 ACE ALPG ALPI ALPL FAS FASLG
7 CD95 death-inducing signaling complex GO:0031265 9.37 CASP10 FAS
8 extracellular space GO:0005615 10.03 ACE ALPL FASLG IFNA1 IL1RN IL2

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 FASLG IFNA1 IL1RN IL2 TNF
2 immune response GO:0006955 9.8 CCR6 FAS FASLG IL1RN IL2 TNF
3 dephosphorylation GO:0016311 9.78 ALPG ALPI ALPL ALPP
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.77 CASP10 FASLG IL1RN NOD2 TNF
5 cellular response to lipopolysaccharide GO:0071222 9.76 IL1RN NOD2 TNF TNFRSF1B
6 positive regulation of JNK cascade GO:0046330 9.74 IL1RN NOD2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.73 ALPL NOD2 TNF
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.72 FASLG TNF TNFRSF1B
9 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.71 CASP10 FAS FASLG TNF
10 response to glucocorticoid GO:0051384 9.7 ALPL IL1RN TNF
11 positive regulation of interleukin-6 production GO:0032755 9.69 IL1RN NOD2 TNF
12 humoral immune response GO:0006959 9.67 CCR6 IFNA1 TNF
13 cytokine-mediated signaling pathway GO:0019221 9.63 FASLG IFNA1 IL1RN IL2 TNF TNFRSF1B
14 apoptotic signaling pathway GO:0097190 9.62 CASP10 FAS FASLG TNF
15 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.6 FAS FASLG
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 TNF TNFRSF1B
17 maintenance of gastrointestinal epithelium GO:0030277 9.58 NOD2 SERPINA3
18 positive regulation of interleukin-17 production GO:0032740 9.58 IL2 NOD2
19 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG TNF TNFRSF1B
20 chronic inflammatory response to antigenic stimulus GO:0002439 9.13 TNF
21 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatase activity GO:0016791 9.46 ALPG ALPI ALPL ALPP
2 cytokine activity GO:0005125 9.35 FASLG IFNA1 IL1RN IL2 TNF
3 alkaline phosphatase activity GO:0004035 8.92 ALPG ALPI ALPL ALPP

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....